Results 291 to 300 of about 4,204,651 (354)
Exploratory Analysis of MicroRNA (miRNA) as a Prognostic and Predictive Biomarker in Locally Advanced and Metastatic Gastric Cancer. [PDF]
CureusL C, Nisha Y, Vishva B, Jafa E, Kate V, G RN, Selvarajan S, Kayal S, Dubashi B, Penumadu P, Ganesan P. +10 moreeuropepmc +1 more sourceRadiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial.
JAMA Netw OpenSeelen LWF, Brada LJH, Walma MS, Rombouts SJE, Braat MN, Bollen TL, Borel Rinkes IH, Bruijnen RCG, Busch OR, Cirkel GA, Daamen LA, Daams F, van Dam RM, van Delden OM, Derksen WJM, Festen S, Groothuis K, Hagendoorn J, de Hingh IHJT, D'Hondt M, Liem MSL, van Lienden KP, Los M, de Meijer VE, Mekenkamp LJM, Nijkamp MW, Nio CY, Pando E, Patijn GA, Polée MB, Te Riele WW, Roeyen G, Stommel MWJ, de Vos-Geelen J, de Vries JJ, Wessels FJ, Wilmink JW, van de Ven PM, Besselink MG, van Santvoort HC, Molenaar IQ, Dutch Pancreatic Cancer Group. +41 moreeuropepmc +1 more sourceSome of the next articles are maybe not open access.Related searches:
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet, The, 2023 BACKGROUND
Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.2), has shown efficacy in patients with CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric K. Shitara, F. Lordick, Y. Bang, P. Enzinger, D. Ilson, M. Shah, Eric Van Cutsem, R. Xu, G. Aprile, Jianming Xu, J. Chao, R. Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob P. Bhattacharya, A. Arozullah, J. Park, Mok Oh, J. Ajani +19 moresemanticscholar +3 more sourcesPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet, The, 2019 BACKGROUND
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater.T. Mok, Yi‐Long Wu, I. Kudaba, D. Kowalski, B. Cho, H. Turna, G. Castro, V. Srimuninnimit, K. Laktionov, I. Bondarenko, K. Kubota, G. Lubiniecki, Jin Zhang, D. Kush, G. Lopes, G. Adamchuk, M. Ahn, A. Alexandru, O. Altundag, A. Alyasova, O. Andrusenko, K. Aoe, A. Araújo, O. Aren, O. Rodríguez, T. Ativitavas, Oscar Avendano, F. Barata, C. Barrios, C. Beato, Per Bergstrom, D. Betticher, L. Bolotina, Michiel Botha, Sayeuri Buddu, C. Caglevic, A. Cardona, H. Castro, F. Senler, Carlos Alexandre Sydow Cerny, A. Česas, G. Chan, Jian-hua Chang, Gongyan Chen, Xi Chen, S. Cheng, Ying Cheng, N. Cherciu, C. Chiu, S. Cicėnas, D. Ciurescu, G. Cohen, Marcos André Costa, P. Danchaivijitr, F. D. Angelis, S. Azevedo, M. Dediu, Ts Deliverski, P. Marchi, Flor de The Bustamante Valles, Z. Ding, Boyan Doganov, L. Dreosti, R. Duarte, Regina T Edusma-Dy, S. Emelyanov, M. Erman, Yun Fan, L. Fein, Jifeng Feng, D. Fenton, G. Fernandes, C. Ferreira, F. Franke, H. Freitas, Y. Fujisaka, H. Galindo, Christina Galvez, D. Ganea, N. Gil, G. Girotto, E. Goker, T. Goksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, H. Griph, M. Gumus, Jacqueline M. Hall, Greg Hart, L. Havel, Jianxing He, Yong He, C. Hernández, V. Hespanhol, T. Hirashima, Chung-man. Ho, A. Horiike, Y. Hosomi, K. Hotta, M. Hou, S. How, T. Hsia, Yi Hu, M. Ichiki, F. Imamura, O. Ivashchuk, Y. Iwamoto, J. Jaal, J. Jassem, Christa Jordaan, R. Juergens, D. Kaen, E. Kalinka‐Warzocha, N. Karaseva, B. Karaszewska, A. Każarnowicz, K. Kasahara, N. Katakami, T. Kato, T. Kawaguchi, J. Kim, K. Kishi, V. Kolek, Marchela Koleva, P. Kolman, L. Koubková, R. Kowalyszyn, D. Kowalski, K. Koynov, D. Ksienski, T. Kurata, G. Kuusk, L. Kuzina, I. Laczó, G. Ladrera, K. Laktionov, G. Landers, S. Lazarev, G. Lerzo, Krzysztof Lesniewski- Kmak, Wei Li, C. Liam, Igor Lifirenko, O. Lipatov, Xiaoqing Liu, Zhe Liu, S. Lo, Valéria Lopes, K. Lopez, Shun Lu, G. Martinengo, L. Mas, M. Matrosova, Rumyana Micheva, Z. Milanova, L. Miron, Tony Mok, M. Molina, S. Murakami, Y. Nakahara, Tien Quang Nguyen, T. Nishimura, A. Ochsenbein, T. Ohira, Ronny Ohman, C. Ong, G. Ostoros, X. Ouyang, E. Ovchinnikova, O. Ozyılkan, L. Petruželka, Xuan Dung Pham, P. Picon, B. Pikó, A. Poltoratsky, Olga Ponomarova, Patrice Popelkova, G. Purkalne, S. Qin, R. Ramlau, Bernardo Rappaport, Felipe Rey, E. Richardet, J. Roubec, P. Ruff, A. Rusyn, H. Saka, J. Salas, Mario Sandoval, L. Santos, T. Sawa, K. Seetalarom, M. Seker, N. Seki, Freddy Seolwane, L. Shepherd, Sergii Shevnya, A. Shimada, Y. Shparyk, I. Sinielnikov, D. Sirbu, O. Smaletz, João Paulo Holanda Soares, A. Sookprasert, G. Speranza, V. Sriuranpong, Zinaida Stara, W. Su, S. Sugawara, W. Szpak, Kazuhisa Takahashi, N. Takigawa, Hiroshi Tanaka, Jerry Tan Chun Bing, Q. Tang, P. Taranov, H. Tejada, L. Tho, Yoshitaro Torii, Dmytro Trukhyn, M. Turdean, H. Turna, G. Ursol, J. Vaňásek, M. Varela, M. Vallejo, Luis Vera, A. Victorino, T. Vlásek, I. Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Yilong Wu, Kazuhiko Yamada, Chih‐Hsin Yang, T. Yokoyama, T. Yokoyama, H. Yoshioka, F. Yumuk, A. Zambrano, J. Zarbá, Oleg Zarubenkov, M. Žemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, A. Zippelius +250 moresemanticscholar +3 more sourcesPerioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet, The, 2019 BACKGROUND
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and ...S. Al-Batran, N. Homann, C. Pauligk, T. Goetze, J. Meiler, S. Kasper, H. Kopp, F. Mayer, G. Haag, K. Luley, U. Lindig, W. Schmiegel, M. Pohl, J. Stoehlmacher, G. Folprecht, S. Probst, N. Prasnikar, W. Fischbach, R. Mahlberg, J. Trojan, M. Koenigsmann, U. Martens, P. Thuss-Patience, M. Egger, A. Block, V. Heinemann, G. Illerhaus, M. Moehler, M. Schenk, F. Kullmann, D. Behringer, M. Heike, D. Pink, C. Teschendorf, C. Löhr, H. Bernhard, G. Schuch, V. Rethwisch, L. V. von Weikersthal, J. Hartmann, M. Kneba, S. Daum, K. Schulmann, J. Weniger, S. Belle, T. Gaiser, F. Oduncu, M. Güntner, W. Hozaeel, Alexander Reichart, E. Jäger, T. Kraus, S. Mönig, W. Bechstein, M. Schuler, H. Schmalenberg, R. Hofheinz +56 moresemanticscholar +3 more sources
